United Therapeutics Corporation (UTHR)

In March 2026, the TETON-1 study for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing meaningful improvement in forced vital capacity (FVC). In April 2026, United Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for miroliverELAP® for the treatment of acute liver failure. On May 6, 2026, United Therapeutics reported its first-quarter 2026 financial results, which missed analyst expectations. In May 2026, UBS raised its price target for United Therapeutics to $705, citing pipeline catalysts and FDA progress. On April 29, 2026, the company announced the retirement of Professor Raymond Dwek from its Board of Directors. Over the last 12 months, the stock price has increased by 85.01%, with a year-to-date return of 16.81%.

Demand seasonality for United Therapeutics Corp.'s products can be observed, with the first quarter often experiencing some impact. In the first quarter of 2026, the company noted that typical historical seasonality trends persisted, and severe winter weather along with pharmacy operations issues slowed patient starts, particularly in February. The company anticipates sequential growth and projects total company revenues to surpass a $4 billion run rate by 2027, with further upside from new indications and products like ralinepag and Tyvaso for IPF, suggesting a generally robust and growing demand for its therapies.

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing products for chronic and life-threatening conditions, particularly pulmonary arterial hypertension (PAH) and lung disease. The company's major commercial therapies for PAH in the United States largely focus on the prostacyclin pathway and are often based on the molecule treprostinil. The company's pipeline also includes promising developments such as ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF). United Therapeutics is also involved in developing manufactured organs, including the UKidney xenotransplantation trial for end-stage renal disease.

United Therapeutics is co-headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, in the United States. The company also has additional facilities in Magog and Bromont, Quebec, Canada; Melbourne and Jacksonville, Florida, United States; Blacksburg, Virginia, United States; Manchester, New Hampshire, United States; and Washington, D.C., United States. The company's revenue is primarily generated in the United States, with operations also extending to the "Rest of the World."

United Therapeutics maintains a strong brand reputation, particularly within the biotechnology and rare disease communities, driven by its patient-centric mission and commitment to innovation. United Therapeutics became the first publicly traded biotechnology company organized as a public benefit corporation in 2021, aligning its legal form with its commitment to serving patients and creating sustainable value for all stakeholders. Positive results from clinical trials for Tyvaso in IPF and ralinepag in PAH, as well as the FDA's Regenerative Medicine Advanced Therapy designation for miroliverELAP®, bolster its scientific and medical credibility. The company has received awards and recognitions for its workplace environment, indicating a positive internal culture that can reflect externally. Its pioneering efforts in organ transplantation and xenotransplantation position it as an innovative leader in addressing significant unmet medical needs.

Approximately 54.63% of the company's stock is owned by institutional investors. Insiders own approximately 1.92% of the company's stock. Public Companies and Individual Investors (Retail Investors) own approximately 43.45% of the stock.